<DOC>
	<DOCNO>NCT01802970</DOCNO>
	<brief_summary>To determine safety administer anakinra plus physician 's chemotherapy choice ( TPC ) nab paclitaxel , capecitabine , eribulin , vinorelbine patient metastatic breast cancer ( MBC ) , well determine blood immune cell transcriptional signature patient undergo IL-1 receptor blockade .</brief_summary>
	<brief_title>Safety Blood Immune Cell Study Anakinra Plus Physician 's Chemotherapy Choice Metastatic Breast Cancer Patients</brief_title>
	<detailed_description>In attempt reverse immune suppressive microenvironment enhance chemotherapy effectiveness , decrease tumor metagenicity decrease IL-1-induced fatigue , metastatic breast cancer ( MBC ) patient treat chemotherapy plus anakinra . This pilot safety , single arm , open label trial . The objective determine safety anakinra plus physician 's chemotherapy choice ( TPC ) nab paclitaxel , capecitabine , eribulin , vinorelbine patient MBC define anakinra-induced anti-IL-1 whole blood transcriptional profile .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Female male patient ≥18 year age . Histologically confirm invasive breast cancer , locally unresectable metastatic . No 4 prior chemotherapy regimens metastatic disease . Patients currently treat nab paclitaxel , capecitabine , eribulin , vinorelbine CR , PR , SD develop Grade 2 , 3 , 4 fatigue chemotherapy eligible study . It anticipate patient continue treat chemotherapy agent least 3 month beyond time enrollment . Prior hormonal therapy adjuvant metastatic setting permit . HER2negative breast cancer . If HER2 , define follow : 1 . FISHnegative ( FISH ratio &lt; 2.0 ) , 2 . IHC 01+ , 3 . IHC 2+ AND FISHnegative ( FISH ratio &lt; 2.0 ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Adequate hematologic function , define : 1 . Absolute neutrophil count ( ANC ) &gt; 1500/mm^3 2 . Platelet count ≥100,000/mm^3 3 . Hemoglobin &gt; 8 g/dL Adequate liver function , define : 1 . AST ALT ≤2.5 x upper limit normal ( ULN ) ≤5 x ULN presence liver metastases 2 . Total bilirubin ≤1.5 x ULN Adequate renal function , define : a. Serum creatinine ≤1.5 x ULN calculate creatinine clearance ≥40 ml/min Measurable nonmeasurable disease RECIST v1.1 criterion Life expectancy ≥24 week Adequate recovery recent surgery 1 . Major surgical procedure &gt; 28 day study entry 2 . Minor surgical procedure &gt; 7 day study entry ( Portacath placement accept patient start treatment &lt; 7 day portacath placement . ) Patients previous history invasive cancer ( include breast cancer ) eligible definitive treatment complete 5 year prior initiate current study treatment , evidence recurrent disease . Patient must accessible treatment followup . All patient must able understand investigational nature study give write informed consent prior study entry Patients active untreated brain metastasis meningeal metastasis ineligible . Patients brain metastasis resect , receive brain radiation therapy &gt; 4 week prior study entry eligible meet follow criterion : 1 ) patient dexamethasone &gt; 2 week ; 2 ) know progression brain metastasis . Previous radiotherapy metastatic disease complete &lt; 2 week prior study treatment initiation . Women pregnant lactating . All patient reproductive potential must agree use effective contraception time study entry least 3 month last administration study drug . Patients severe and/or uncontrolled medical condition condition could affect participation : 1. severe impair lung function define spirometry DLCO 50 % normal predict value and/or O2 saturation 88 % less rest room air 2. uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN 3. liver disease cirrhosis severe hepatic impairment ( ChildPugh class C ) . History disease , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , might affect interpretation result study , render subject high risk treatment complication . Patients may receive investigational treatment participate study . Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent . Topical inhale corticosteroid allow . Concurrent severe , uncontrolled infection intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Anakinra</keyword>
	<keyword>Nab Paclitaxel</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Eribulin</keyword>
	<keyword>Vinorelbin</keyword>
</DOC>